TREX1 in cancer immunity: from molecular mechanism to pharmacological targeting
Abstract
Three-prime repair exonuclease 1 (TREX1) is a 3’→5’ exonuclease that degrades cytoplasmic DNA to prevent aberrant activation of innate immune responses. During tumorigenesis, TREX1 expression is frequently dysregulated in a cancer type-specific manner, leading to suppression of the cGAS-STING signaling pathway and reduced type I interferon (IFN-I) production, thereby facilitating tumor immune evasion in certain tumor contexts. Additionally, altered TREX1 expression is associated with chromosomal instability and cancer stem cell characteristics, promoting tumor invasion and metastasis in a context-dependent manner. Pharmacological inhibition or genetic deletion of TREX1 significantly enhances the efficacy of immune checkpoint inhibitors and STING agonists in preclinical models, indicating its potential as an immunotherapeutic target.Some inhibitors have shown selective inhibition potential against TREX1 in preclinical studies, but the selectivity for TREX2 still requires further validation. Moreover, TREX1-deficient tumor cells can serve as autologous cancer vaccines by promoting immunogenic cell death and enhancing CD8+ T cell and NK cell activation in preclinical models. This review systematically summarizes the molecular mechanisms of TREX1 in tumorigenesis and immune escape, discusses the pharmacological strategies for TREX1 targeting, and evaluates the therapeutic potential and challenges of TREX1-based immunotherapy, providing a theoretical foundation for clinical translation.
Related
- The Tango of cGAS-STING and Phagocytosis in Disease: From Molecular Mechanisms to Pharmacological Targeting.
- Molecular mechanism by which SARS-CoV-2 Orf9b suppresses the Tom70-Hsp90 interaction to evade innate immunity
- Beyond gene signatures: a mechanism-based framework for cuproptosis susceptibility in non-small cell lung cancer at the metabolism–immunity interface
- ULBP2–NKG2D signaling in cancer immunity: immune surveillance, immune escape, and therapeutic targeting
- Selective targeting of M2-like tumor-associated macrophages by TB511 promotes NK cell-associated antitumor immunity in prostate cancer
BibTeX
@article{wu2026trex1,
title = {{TREX1 in cancer immunity: from molecular mechanism to pharmacological targeting}},
author = {Yuan-Yuan Wu and Wei-Lan Li and Hua Shao and Lingli Huang},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1967881},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1967881},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - TREX1 in cancer immunity: from molecular mechanism to pharmacological targeting
AU - Yuan-Yuan Wu
AU - Wei-Lan Li
AU - Hua Shao
AU - Lingli Huang
PY - 2026
DA - 2026/11/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1967881
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1967881
AB - Three-prime repair exonuclease 1 (TREX1) is a 3’→5’ exonuclease that degrades cytoplasmic DNA to prevent aberrant activation of innate immune responses. During tumorigenesis, TREX1 expression is frequently dysregulated in a cancer type-specific manner, leading to suppression of the cGAS-STING signaling pathway and reduced type I interferon (IFN-I) production, thereby facilitating tumor immune evasion in certain tumor contexts. Additionally, altered TREX1 expression is associated with chromosomal instability and cancer stem cell characteristics, promoting tumor invasion and metastasis in a context-dependent manner. Pharmacological inhibition or genetic deletion of TREX1 significantly enhances the efficacy of immune checkpoint inhibitors and STING agonists in preclinical models, indicating its potential as an immunotherapeutic target.Some inhibitors have shown selective inhibition potential against TREX1 in preclinical studies, but the selectivity for TREX2 still requires further validation. Moreover, TREX1-deficient tumor cells can serve as autologous cancer vaccines by promoting immunogenic cell death and enhancing CD8+ T cell and NK cell activation in preclinical models. This review systematically summarizes the molecular mechanisms of TREX1 in tumorigenesis and immune escape, discusses the pharmacological strategies for TREX1 targeting, and evaluates the therapeutic potential and challenges of TREX1-based immunotherapy, providing a theoretical foundation for clinical translation.
SN - 1664-3224
ER -